SUMO Biosciences Inc. develops next generation small molecule immuno oncology drugs to address unmet medical needs in aggressive lymphoma and in colorectal cancers. The SUMO E1 enzyme is a novel immuno oncology target. We have discovered an allosteric mechanism to inhibit the SUMO E1 enzyme, and use this approach to develop small molecule drugs that are orally available and straight forward to synthesize. The team has extensive expertise in SUMO modification biology and in small molecule drug discovery. We have filed multiple patents.